Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyka LabsBOM:500259 +3.18%53 Net Current Asset Value is ₹-5.29 as of Mar. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 53/100 and a GF Value™ of ₹127.67 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 935 Biotechnology companies, Lyka Labs ranks worse than 106951.76% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Lyka Labs's net current asset value per share for the quarter that ended in Mar. 2026 was ₹-5.29.
The historical rank and industry rank for Lyka Labs's Net Current Asset Value or its related term are showing as below:
BOM:500259's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 4.51 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Lyka Labs (BOM:500259) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Lyka Labs Net Current Asset Value Related Terms
Lyka Labs Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, RVMD: Net Current Asset Value Comparison
For the Biotechnology subindustry, Lyka Labs's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹-5.29 mean?
Lyka Labs (BOM:500259) has a Net Current Asset Value of ₹-5.29 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Lyka Labs and its competitors. According to the industry distribution chart, Lyka Labs ranks #999999 out of 935 companies in the Biotechnology industry.
Is Lyka Labs' Net Current Asset Value too high?
Lyka Labs' current Net Current Asset Value is ₹-5.29. Based on the distribution chart, Lyka Labs ranks #999999 out of 935 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyka Labs has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #999999 out of 935 companies for Net Current Asset Value. This places Lyka Labs in the lower half of its industry. The industry median Net Current Asset Value is 4.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.51, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Lyka Labs and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyka Labs's current Net Current Asset Value is ₹-5.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.67, compared to a current price of ₹63.25 — trading 50.5% below its estimated fair value. The current Net Current Asset Value is ₹-5.29. Lyka Labs' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Net Current Asset Value is ₹-5.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹63.25 is trading 50.5% below its estimated GF Value™ of ₹127.67.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Net Current Asset Value: ₹-5.29
GF Value™: ₹127.67 vs. price of ₹63.25 (50.5% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
53GF Score
Get the complete analysis for BOM:500259
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
